Company intelligence / Profile preview
Vigonvita Life Sciences
Suzhou, Jiangsu, Chinaen.vigonvita.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vigonvita Life Sciences is a Chinese biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of innovative small molecule drugs. Its lead product VV116 (deuremidevir hydrobromide) is approved for COVID‑19 treatment in China and Uzbekistan under the trade names Mindvy®/MINDVY®, with ongoing late-stage trials for RSV. The company’s pipeline spans viral infections (including SFTS virus and adenovirus), neuropsychiatric disorders (major depression, schizophrenia), reproductive health issues (premature ejaculation), and epilepsy. It has end-to-end capabilities from research through manufacturing.[1][2][6]
- Therapeutic areas
- Men's HealthPsychiatryNeurologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Junshi Biosciences – co-development/commercialization partner for lead antiviral drug VV116 globally except certain regions. Junshi holds rights outside China/Central Asia/MENA/Russia while Vigonvita supplies API ingredients to Hainan-based manufacturer.Chinese Academy of Sciences/Suzhou Research Institute – strategic academic partnership/incubation support since founding.Lingang Laboratory – involved in collaborative research on antivirals including COVID therapies alongside Junshi/Vigonvita.
Beyond the preview
Go deeper on Vigonvita Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vigonvita Life Sciences.